Renoprotective effects of benazepril: current perspective

Stompór, Tomasz; Napora, Maria; Olszewski, A.

doi:10.1586/erc.11.55

Cited by 5 publications

(5 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13 Benazepril is a medicine used to treat high blood pressure, heart failure, and diabetic kidney disease. 14 The US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing utosomal dominant polycystic kidney disease. 15…”

Section: Table 1 Optimization Of the Reaction Condition...mentioning

confidence: 99%

Palladium-Catalyzed Oxidative Cycloaddition of Quinazoline-2,4(1H,3H)-diones and Diarylalkynes via C–H/N–H Activation

et al. 2023

View full text Add to dashboard Cite

The oxidative cycloaddition of 3-subsituted quinazoline-2,4(1H,3H)-diones and alkynes has been developed. The reaction is Pd(II)-catalyzed and successfully occurs in the presence of Ag(I) oxidants. This transformation is assumed to proceed by N-H palladation of the quinazoline-2,4(1H,3H)-dione followed by ortho C-H activation. Using this methodology, a series of 5,6,7,8-tetraaryl-1H-azepino[3,2,1-ij]quinazoline-1,3(2H)-diones were obtained in moderate to good yields. The resulting tricyclic heterocycles can be converted by alkaline hydrolysis into 1H-benzo[b]azepine-9-carboxamide derivatives. DFT calculations have been carried out to shed light on the reaction mechanism.

show abstract

Section: Table 1 Optimization Of the Reaction Condition...mentioning

confidence: 99%

Palladium-Catalyzed Oxidative Cycloaddition of Quinazoline-2,4(1H,3H)-diones and Diarylalkynes via C–H/N–H Activation

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Heart failure (HF) is a clinical syndrome that results from highly prevalent disorders in our society, including chronic hypertension and coronary artery disease. Most guidelines promote early treatment, including the use of ACEIs to control Cardiovascular (CV) risk in patients with chronic renal failure [1][2]. ACEIs play an indispensable role in the treatment of a variety of disorders including hypertension, CHF, and in the prevention of diabetic nephropathy [3].…”

Section: Introductionmentioning

confidence: 99%

“…ACEIs play an indispensable role in the treatment of a variety of disorders including hypertension, CHF, and in the prevention of diabetic nephropathy [3]. The renoprotective effects and independent of blood pressure control of the ACEIs, benazepril, have been demonstrated [2] However, Lin-Hua Tan [4] reported a case with reversible acute renal failure in a premature neonate with double outlet right ventricle and CHF induced by Captopril. The tolerance of ACEIs to renal need to be carefully monitored.…”

Section: Introductionmentioning

confidence: 99%

Benazepril induced acute kidney injury (AKI) in a patient with congestive heart failure (CHF) and moderate chronic kidney disease (CKD): A case report

Hn¹,

Dn²,

Lq³

et al. 2019

Blood Heart Circ

View full text Add to dashboard Cite

Angiotensin-converting enzyme inhibitors (ACEIs) was demonstrated protective effect for patients with mild to moderate chronic kidney disease (CKD). The ACEIs was usually applied to patients while his serum creatinine (Scr) levels were no more than 3.0 mg/dL. However, it could induce AKI even in the patients with mild to moderate CKD combined with CHF. We report a case of a 62-year-old male with CHF and moderate CKD (SCr: 1.9 mg/dL) who subsequently and transiently develop AKI after he was administrated benazepril 2.5mg/day. Using the Naranjo, benazepril was found to be a probable cause of AKI in the patient. ACEIs, classified as RAAS inhibitors, can induce AKI in some conditions. Attention should be given to benazepril therapy in patients with mild to moderate CKD and CHF. Routine hemodynamic examination and biochemical monitoring was suggested before and during the period of benazepril therapy.

show abstract

“…The ACCOMPLISH trial is the largest investigation to date to demonstrate the additional advantage of combining ACE inhibitors with calcium-channel blockers in renal protection, even though the patients in this study did not have overt renal impairment (instead, they had serious cardiovascular conditions)[21]. Piero et al(2019) In patients with type 2 diabetes and overt nephropathy, to determine whether combination therapy with angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker is more nephroprotective than either agent alone.…”

mentioning

confidence: 98%

“…Tomasz et al (2011) The GUARD (Gauging Albuminuria Reduction with Lotrel in Diabetic Patients with Hypertension) trial showed that benazepril/hydrochlorothiazide was more effective than amlodipine combined with benazepril in reducing baseline urinary albumin:creatinine ratio and normalizing urinary albumin: creatinine ratio in patients with baseline microalbuminuria, although this effect was accompanied by a greater decrease in glomerular filtration rate than with benazepril/amlodipine. In the ACCOMPLISH (Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension) trial, patients who received benazepril in combination with amlodipine experienced better CV outcomes and renoprotective effects.…”

mentioning

confidence: 99%

Effectiveness And Safety Measures Of Benazepril Hydrochloride On Diabetic Nephropathy

Prakash,

Sarkar,

Kumar

et al. 2023

jaz

View full text Add to dashboard Cite

One of the most common chronic microvascular consequences of diabetes, diabetic nephropathy (DN) affects a significant number of individuals globally. The International Diabetes Federation (IDF) reports that there are 37 million diabetes people globally, with around 4.6 million of them passing away in 2011. The current review was based on the effectiveness and toxicity of Benazepril Hydrochloride on Diabetic Nephropathy. Benazepril is a prodrug that consists of an extremely low inhibitory action ethyl ester, a carboxylic acid group, and the benzepine nucleus with a phenyl-propyl side chain. The FDA has approved benazepril hydrochloride for the treatment of hypertension, either by itself or in conjunction with other antihypertensive medications. Anaphylactoid reactions and angioedema, which can include tongue edema and laryngeal angioedema, are examples of sensitivity reactions that have the potential to be lethal. Renal dysfunction and electrolyte imbalances are linked to hypotension. In the second and third trimesters of pregnancy, the use of medications that affect the reninangiotensin system decreases fetal renal function and increases morbidity and mortality in the fetus and newborn. The most prevalent indicator of toxicity is low blood pressure. In additions, lack of energy, increased salivation, elevated heart rate, vomiting, diarrhoea, weakness, coughing, bronchospasms, and kidney malfunction are other indicators of toxicity. In conclusion, in the management of diabetic nephropathy combination therapy-benazepril with spironolactone or diuretic is recommended. It heals the nephrons which have been affected due to the toxicity of various drugs or infections.

show abstract

Renoprotective effects of benazepril: current perspective

Cited by 5 publications

References 71 publications

Palladium-Catalyzed Oxidative Cycloaddition of Quinazoline-2,4(1H,3H)-diones and Diarylalkynes via C–H/N–H Activation

Palladium-Catalyzed Oxidative Cycloaddition of Quinazoline-2,4(1H,3H)-diones and Diarylalkynes via C–H/N–H Activation

Benazepril induced acute kidney injury (AKI) in a patient with congestive heart failure (CHF) and moderate chronic kidney disease (CKD): A case report

Effectiveness And Safety Measures Of Benazepril Hydrochloride On Diabetic Nephropathy

Contact Info

Product

Resources

About